Viewing Study NCT02348905


Ignite Creation Date: 2025-12-25 @ 3:11 AM
Ignite Modification Date: 2025-12-26 @ 1:49 AM
Study NCT ID: NCT02348905
Status: UNKNOWN
Last Update Posted: 2015-01-28
First Post: 2014-06-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial
Sponsor: Albany Medical College
Organization:

Study Overview

Official Title: ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial
Status: UNKNOWN
Status Verified Date: 2015-01
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: ACTHAR gel has efficacy in the treatment of cutaneous sarcoidosis
Detailed Description: Sarcoidosis is a multisystem granulomatous disease of unknown cause. Although sarcoidosis most commonly affects the lung3, it may affect any organ. Although corticosteroids are recognized as the drug of choice for sarcoidosis, ACTH is the only drug that is FDA-approved for this disorder. However, there is limited data on the efficacy of ACTH for this condition.

Presently, corticosteroids as considered the drug of choice for the treatment of cutaneous sarcoidosis. However, ACTHER GEL not only has obvious anti-inflammatory effects by resulting in corticosteroid production, but it may also activate melanocortin receptors. The melanocortin system has powerful anti-inflammatory properties that may be beneficial in the treatment of cutaneous sarcoidosis.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: